Related Experiment Video
Updated: Jul 13, 2025
06:11
A High-throughput Shigella-specific Bactericidal Assay
Published on: February 27, 2019
11.8K
Vaccine value profile for Shigella
William P Hausdorff1, John D Anderson2, Karoun H Bagamian3
1Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA; Faculty of Medicine, Université de Bruxelles, Brussels 1070, Belgium.
Vaccine
|October 12, 2023
Summary
Developing a Shigella vaccine is a global health priority, especially for children in low- and middle-income countries (LMICs). This Vaccine Value Profile assesses current data to guide the development of effective Shigella vaccines.
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health
Background:
- Shigella is a major cause of bacterial diarrhea and mortality, particularly in children under five in LMICs.
- Increasing antibiotic resistance in Shigella necessitates urgent vaccine development.
- The World Health Organization (WHO) prioritizes a safe, effective, and affordable Shigella vaccine.
Purpose of the Study:
- To provide a holistic assessment of available data for Shigella vaccine candidates.
- To inform the potential public health, economic, and societal value of pipeline Shigella vaccines.
- To identify current research and knowledge gaps in Shigella vaccine development.
Main Methods:
- Development of a Vaccine Value Profile (VVP) for Shigella.
- Utilized existing and publicly available information.
- Involved a working group of subject matter experts from diverse organizations.
Main Results:
- Advanced vaccine candidates include multivalent parenteral formulations in Phase 2/3 clinical trials.
- Emerging formulations involve O-antigen-polysaccharide protein conjugates or detoxified outer membrane vesicles.
- Earlier-stage candidates explore broader antigen delivery via parenteral and oral routes.
Conclusions:
- Shigella vaccines are crucial for reducing disease burden, antibiotic use, and antimicrobial resistance.
- Pipeline vaccines are being evaluated against WHO Preferred Product Characteristics for infant immunization.
- The VVP highlights the need for continued research to address knowledge gaps and maximize vaccine value.
